The APEX data are strong and the NDA submission timeline is near-term (June 2026), which de-risks the regulatory path. Traders should watch for FDA acceptance of the NDA and any AdCom vote as the next catalysts.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 12 $33.10entry
- T+1 · 5mo ago +0.21%α −1.55% · $33.17
- T+5 · 5mo ago +4.35%α +3.68% · $34.54
- T+20 · 4mo ago +17.43%α +15.65% · $38.87
- T+60 · 2mo ago +6.59%α +3.32% · $35.28
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cogent Biosciences reported updated Phase 2 APEX trial results for bezuclastinib in advanced systemic mastocytosis (AdvSM) at EHA 2026, showing a 65% objective response rate per mIWG criteria and 81% per PPR criteria, with 91% of patients achieving ≥50% reduction in KIT D816V variant allele frequency. The company plans to submit an NDA in June 2026 and expects commercial launch later this year.
Key Facts
- Updated APEX trial data: 65% ORR per mIWG criteria (CR+CRh+PR+CI) and 81% ORR per PPR criteria in AdvSM patients.
- 91% of patients achieved ≥50% reduction in KIT D816V variant allele frequency; 89% had ≥50% reduction in bone marrow mast cells or clearance of aggregates.
- 12-month PFS rate of 79% and 12-month OS rate of 87%.
- NDA submission for bezuclastinib in AdvSM planned for June 2026.
- Company expects commercial launch in both systemic mastocytosis and GIST later this year following FDA approval.
- Safety profile manageable: most common TRAEs were hair color change (31%), neutropenia (31%), altered taste (28%), thrombocytopenia (25%), and ALT/AST elevations (21%), mostly low-grade.
Financial Impact
No financial data provided; bezuclastinib is Cogent's lead asset and potential approval would transform the company from pre-revenue to commercial-stage. Systemic mastocytosis and GIST represent multi-billion-dollar market opportunities.
Risk Factors
- FDA could issue a Complete Response Letter (CRL) on CMC or clinical grounds, delaying approval.
- Competition from approved KIT inhibitors (e.g., avapritinib) could limit commercial uptake.
- Commercial launch execution risk for a first-time product.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311014 |
Track record
13 reports on COGT
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +11.18% at T+20 after the May 30, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $33.54 Now $27.44 −18.19% settles Feb 5
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $31.65 Now $27.44 −13.29% settles Feb 4
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Aug 9, 202614w ago Institutional Cluster Bullish 6/10 Entry $41.53 to $31.06 Now $27.44 −33.93% ▼ −25.21% −22.79% vs SPY
- Jun 12, 202622w ago Press Release Neutral 4/10 Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- Jun 12, 202622w ago Press Release Bullish 7/10 Viewing Entry $33.10 to $35.28 Now $27.44 −17.10% ▲ +6.59% +3.32% vs SPY
- May 30, 202624w ago Press Release Bullish 8/10 Entry $34.81 to $36.80 Now $27.44 −21.17% ▲ +5.72% +4.49% vs SPY
- May 28, 202624w ago Press Release Bullish 8/10 Entry $35.38 to $36.73 Now $27.44 −22.44% ▲ +3.82% +2.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers